Modifies provisions relating to limits on selling or purchasing certain drugs
Summary
HB 1036 revises Missouri’s laws governing over-the-counter methamphetamine precursor drugs, primarily products containing ephedrine, pseudoephedrine, or phenylpropanolamine. The bill repeals and reenacts sections 195.417 and 579.060 to update purchase and sale limits, including a 7.2-gram limit over 30 days, a 3.6-gram limit over 24 hours, and an increased annual limit from 43 grams to 61.2 grams. It also preserves the rule that these products generally do not require a prescription when purchased within the statutory limits.
The bill keeps these products behind the pharmacy counter, requires pharmacies to submit sales information under department-established reporting procedures, and maintains criminal penalties for knowing or reckless violations. It also adds a manufacturer fee requirement tied to the real-time electronic pseudoephedrine tracking system beginning October 1, 2025, and authorizes the Department of Health and Senior Services to request proof of payment. The bill continues to preempt local ordinances on these products and voids certain local prescription requirements that were enacted before August 28, 2020.
Impact
HB 1036 would amend Missouri’s controlled-substance and pharmacy-related statutes by replacing the current limits and enforcement provisions for pseudoephedrine and related precursor drugs. It affects sellers, pharmacists, pharmacy technicians, manufacturers, and purchasers by changing quantity thresholds, reaffirming behind-the-counter placement, expanding reporting and tracking obligations, and creating a new manufacturer fee structure. It also preserves and clarifies criminal penalties under section 579.060, including class A misdemeanor liability for unlawful sale, distribution, or purchase of these precursor drugs.
Sentiment
The available record does not include committee testimony or recorded votes, so there is no direct evidence of support or opposition from the legislative process. Based on the bill text, the measure appears to be framed as a public-safety and anti-methamphetamine enforcement update rather than a major policy shift, suggesting a generally regulatory and enforcement-oriented posture. The absence of discussion transcripts makes it difficult to identify any broader political sentiment beyond the bill’s apparent intent to tighten oversight while preserving lawful access within set limits.
Contention
The main points of contention likely concern the balance between restricting access to methamphetamine precursor drugs and preserving legitimate consumer access to cold and allergy medications. Pharmacies and manufacturers may be affected by the reporting, tracking, and fee provisions, while local governments may object to the bill’s express preemption of local ordinances and invalidation of certain local prescription requirements. Law enforcement and public-health interests are likely to support the tighter controls and tracking measures, while retail and pharmacy stakeholders may focus on compliance burdens and operational costs.